Quick Answer
TriSalus Life Sciences, Inc. reported Stockholders Equity of -$33.86 million for fiscal year 2025.
TriSalus Life Sciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$33.86M | -30.8% |
| 2024 | -$25.89M | +4.3% |
| 2023 | -$27.07M | +84.7% |
| 2022 | -$177.13M | -36.7% |
| 2021 | -$129.60M | -503.3% |
| 2020 | -$21.48M | — |
| 2020 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$26.73M | -30.8% | -37.6% |
| June 30, 2025 | -$19.42M | +23.1% | +43.5% |
| March 31, 2025 | -$34.37M | +4.6% | -32.7% |
| December 31, 2024 | -$25.89M | +4.3% | -26.7% |
| September 30, 2024 | -$20.43M | -346.4% | +19.1% |
| June 30, 2024 | -$25.26M | +87.3% | +29.9% |
| March 31, 2024 | -$36.04M | +80.5% | -33.1% |
| December 31, 2023 | -$27.07M | +84.7% | -426.4% |
- TriSalus Life Sciences, Inc. showed a decrease of -30.8% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from TriSalus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: